FDA approves first drug for primary progressive multiple sclerosis

Nature Reviews Drug Discovery 16, 305 (2017). doi:10.1038/nrd.2017.88 Author: Asher Mullard The FDA approved Roche's ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis (PPMS), wrapping up a 40-year development history for the anti-CD20 monoclonal antibody (mAb). This is the first drug approval for PPMS, a form of the neurodegenerative disease that
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research